0000000000298729

AUTHOR

F Menzella

showing 3 related works from this author

Characteristics and treatment regimens across ERS SHARP severe asthma registries

2020

Little is known about the characteristics and treatments of patients with severe asthma across Europe, but both are likely to vary. This is the first study in the European Respiratory Society Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) Clinical Research Collaboration and it is designed to explore these variations. Therefore, we aimed to compare characteristics of patients in European severe asthma registries and treatments before starting biologicals.This was a cross-sectional retrospective analysis of aggregated data from 11 national severe asthma registries that joined SHARP with established patient databases.Analysis of data from 3236 patients showed many …

Severe asthmaPediatricsMESH: RegistriesMESH: AsthmaCross-sectional studyRespiratory SystemMedizin[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract0302 clinical medicineMESH: BelgiumBelgiumMedicine researchAnti-Asthmatic AgentsRegistries030212 general & internal medicine[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology10. No inequality11 Medical and Health SciencesNetherlands2. Zero hungereducation.field_of_studySHARP CRCMESH: Administration InhalationMESH: Anti-Asthmatic Agents3. Good healthEuropeItalyMESH: PolandMESH: Swedenmedicine.drugPulmonary and Respiratory Medicinemedicine.medical_specialtyMESH: HungaryPopulationInvestigació mèdicaSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesMESH: Cross-Sectional StudiesAdministration InhalationMESH: SpainmedicineHumanseducationAsmaRetrospective StudiesAsthmaSwedenHungaryMESH: Humansbusiness.industrySettore MED/09 - MEDICINA INTERNAMESH: ItalyMESH: Retrospective StudiesRetrospective cohort studyOriginal Articlesasthmamedicine.diseaseAsthmaClinical trialCross-Sectional StudiesClinical research030228 respiratory systemSpainMESH: NetherlandsMESH: EuropePolandbusinessBody mass indexMepolizumabEuropean Respiratory Journal
researchProduct

International prevalence and risk factors evaluation for drug-resistant Streptococcus pneumoniae pneumonia

2019

Objective: Streptococcus pneumoniae is the most frequent bacterial pathogen isolated in subjects with Community-acquired pneumonia (CAP) worldwide. Limited data are available regarding the current global burden and risk factors associated with drug-resistant Streptococcus pneumoniae (DRSP) in CAP subjects. We assessed the multinational prevalence and risk factors for DRSP-CAP in a multinational point-prevalence study. Design: The prevalence of DRSP-CAP was assessed by identification of DRSP in blood or respiratory samples among adults hospitalized with CAP in 54 countries. Prevalence and risk factors were compared among subjects that had microbiological testing and antibiotic susceptibility…

0301 basic medicineMaleStreptococcus pneumoniaantibiotic resistanceInternationalitysputum examinationbronchiectasisvery elderlyAntibioticsPrevalenceDrug resistancemedicine.disease_causeLogistic regressionGlobal HealthCommunity-Acquired Infections/epidemiologylung lavage0302 clinical medicineCommunity-acquired pneumoniaCost of IllnessRisk FactorsPrevalencedrug resistant Streptococcus pneumoniae pneumonia030212 general & internal medicineMicrobial drug resistantAged 80 and overadultinternational cooperationdrug effectMiddle Agedinfluenza vaccinationAnti-Bacterial Agentsantiinfective agentEuropeCommunity-Acquired InfectionsHospitalizationGlobal burden of diseaseStreptococcus pneumoniaeInfectious Diseasesrisk factorbacterium identificationFemalecommunity acquired infectioninfluenzaliver diseasepneumococcal vaccinationPneumococcal infectionhospitalizationmedicine.drugMicrobiology (medical)medicine.medical_specialtyAsiamedicine.drug_class030106 microbiologySettore MED/10 - Malattie Dell'Apparato RespiratorioArticleAnti-Bacterial Agents/pharmacology03 medical and health sciencesInternal medicineStreptococcus pneumoniaeDrug Resistance BacterialPneumonia Pneumococcal/epidemiologymedicineHumanscontrolled studyhumantetracyclineHospitalization/statistics & numerical dataAgedlevofloxacinnonhumanbusiness.industrydisease associationmicrobiologycommunity acquired pneumoniamacrolidePneumoniaasthmaSouth AmericaPneumonia Pneumococcalvaccinationmedicine.diseasemajor clinical studyantibiotic sensitivitypenicillin derivativePenicillinStreptococcus pneumoniae/drug effectsPneumoniablood examinationAfricaNorth Americamicrobiological examinationbusinessGlobal burden of disease; Microbial drug resistant; Pneumococcal infection; Pneumonia
researchProduct

COVID-19 in Severe Asthma Network in Italy (SANI) patients: Clinical features, impact of comorbidities and treatments

2020

To the Editor Since the end of February 2020 Italy, first non- Asian Country, has reported an ever increasing number of COronaVIrus Disease 19 (COVID-19) patients, which has reached over 200,000 confirmed Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) infected subjects and resulted in more than 34000 deaths (data updated to June 19th, 20201).Patients with asthma are potentially more severely affected by by SARS-CoV-2 infection 2 and it is well established that respiratory viral infections are associated with severe adverse outcomes in patients with asthma, including increased risk of asthma exacerbation episodes 3. Nonetheless, according to the epidemiological studies publishe…

severe asthmamedicine.medical_specialty2019-20 coronavirus outbreakCOVID-19 Severe Asthma Network in Italy inflammationCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Severe asthmaPopulationImmunologyMEDLINEOmalizumabSettore MED/10 - Malattie Dell'Apparato RespiratorioNOInternal medicineDiabetes mellitusSeverity of illnessmedicineImmunology and AllergyRisk factorLetters to the EditoreducationLetter to the EditorAsthmaeducation.field_of_studybusiness.industryIncidence (epidemiology)Mortality rateCOVID-19medicine.diseaseComorbiditySevere Asthma Network in ItalyinflammationCohortbusinessMepolizumabmedicine.drug
researchProduct